structure_inline_fullcolor_rgb_12in@300ppi.png
Structure Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional American Depositary Shares
February 07, 2023 16:00 ET | Structure Therapeutics Inc.
SAN FRANCISCO and SHANGHAI, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule...
structure_inline_fullcolor_rgb_12in@300ppi.png
硕迪生物宣布完成经增发的首次公开募股包括承销商全面行使购买额外美国存托股票的选择权
February 07, 2023 16:00 ET | Structure Therapeutics Inc.
旧金山和上海, Feb. 08, 2023 (GLOBE NEWSWIRE) --...
structure_inline_fullcolor_rgb_12in@300ppi.png
硕迪生物宣布经增发的首次公开募股的定价
February 02, 2023 20:59 ET | Structure Therapeutics Inc.
加利福尼亚州旧金山和中国上海, Feb. 03, 2023 (GLOBE NEWSWIRE) -- 硕迪生物技术有限公司（纳斯达克股票代码：GPCR）是一家临床阶段的全球化生物制药公司，致力于口服小分子药物的创新研发以治疗代谢性和肺部疾病。今日，公司宣布其经增发的首次公开募股的定价。公司拟发行10,740,000股美国存托股票（ADS），每股ADS代表三股普通股，公开发行价格为每股ADS...
structure_inline_fullcolor_rgb_12in@300ppi.png
Structure Therapeutics Announces Pricing of Upsized Initial Public Offering
February 02, 2023 19:41 ET | Structure Therapeutics Inc.
SAN FRANCISCO and SHANGHAI, China, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small...
ResearchDriveLogo.jpg
Global Computer-Aided Drug Discovery Market Predicted to Garner the Revenue of $4,878.5 billion by 2026 during the Forecast Period – Exclusive Report [170 Pages] by Research Dive
November 09, 2020 09:05 ET | Research Dive
New York, USA, Nov. 09, 2020 (GLOBE NEWSWIRE) -- The global computer-aided drug discovery market is expected to garner a revenue of $ 4,878.5 billion million at a CAGR of 15.5% by 2026, increasing...